This is a working overview of certificate of analysis, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-07-17. Anything still debated is marked as such rather than presented as settled.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C20H24ClN3O4S | Reported for the free base |
| Molecular weight | 437.9 g/mol | Calculated from the formula |
| Primary target | REV-ERBα and REV-ERBβ | Nuclear receptors involved in circadian regulation |
| Solubility | Soluble in DMSO and ethanol | Poorly soluble in water |
| Typical storage | -20 °C, desiccated | Protect from light and moisture |
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
The various quantities of a particular element involved in the constitution of different molecules are integral multiples of a fundamental quantity that always manifests itself as an indivisible entity and which must properly be named atom. A second objection to atomic theory was philosophical. Scientists in the 19th century had no way of directly observing atoms. They inferred the existence of atoms through indirect observations, such as Dalton's law of multiple proportions. Some scientists adopted positions aligned with the philosophy of positivism, arguing that scientists should not attempt to deduce the deeper reality of the universe, but only systemize what patterns they could directly observe. This generation of anti-atomists can be grouped in two camps. The "equivalentists", like Marcellin Berthelot, believed the theory of equivalent weights was adequate for scientific purposes. This generalization of Proust's law of definite proportions summarized observations. For example, 1 gram of hydrogen will combine with 8 grams of oxygen to form 9 grams of water, therefore the "equivalent weight" of oxygen is 8 grams. These ideas where widely used by chemists without accepting an underlying atomic explanation. The "energeticists", like Ernst Mach and Wilhelm Ostwald, were philosophically opposed to hypothesis about reality altogether. In their view, only energy as part of thermodynamics should be the basis of physical models.
=== European Union === Hitchens was a supporter of the European Union. In an appearance on C-SPAN in 1993, Hitchens said, "As of 1992, there is a now a Euro passport that makes you free to travel within the boundaries of... member countries, and I've always liked the idea of European unity, and so I held out for a Euro passport. So I travel as a European." Speaking at the launch of his brother Peter Hitchens' book, The Abolition of Britain at Conway Hall in London, Hitchens denounced the so-called Eurosceptic movement, describing it as "the British version of fascism". He went on to say, "Scepticism is a title of honour. These people are not sceptical. They're fanatical. They're dogmatic".
=== Depolymerization techniques === Either chemical or enzymatic depolymerization techniques or a combination of the two underlie the vast majority of analyses carried out on the structure and function of heparin and heparan sulfate (HS).
== Hazards == Bottles of di-tert-butyl dicarbonate buildup of internal pressure in sealed containers caused by its slow decomposition to di-tert-butyl carbonate and ultimately tert-butanol and CO2 in the presence of moisture. For this reason, it is usually sold and stored in plastic bottles rather than glass ones. The main hazard of the reagent is its inhalational toxicity. Its median lethal concentration of 100 mg/m3 over 4 hours in rats is comparable to that of phosgene (49 mg/m3 over 50 min in rats).
=== Biosynthesis === In terms of biosynthesis, oxycodone has been found naturally in nectar extracts from the orchid family Epipactis helleborine; together along with other chemicals: 3-{2-{3-{3-benzyloxypropyl}-3-indol and 7,8-didehydro-4,5-epoxy-3,6-d-morphinan. Thodey et al., 2014 introduce a microbial compound manufacturing system for compounds including oxycodone. The Thodey platform produces both natural and semisynthetic opioids including this one. This system uses Saccharomyces cerevisiae with transgenes from Papaver somniferum (the opium poppy) and Pseudomonas putida to turn a thebaine input into other opiates and opioids.
Sources: en.wikipedia.org
== Medical uses == Trastuzumab deruxtecan is indicated for the treatment of adults with unresectable (unable to be removed with surgery) or metastatic (when cancer cells spread to other parts of the body) HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting and for adults with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma who have received a prior trastuzumab-based regimen. In May 2022, the US Food and Drug Administration (FDA) expanded the indication to include the treatment of adults with unresectable or metastatic HER2-positive breast cancer who have received a prior anti-HER2-based regimen either in the metastatic setting, or in the neoadjuvant or adjuvant setting and have developed disease recurrence during or within six months of completing therapy. In August 2022, the FDA expanded the indication to include the treatment of unresectable or metastatic HER2-low breast cancer. In April 2024, the FDA expanded the indication to include the treatment of unresectable or metastatic HER2-positive (IHC3+) solid tumors for adults who have received prior systemic treatment and have no satisfactory alternative treatment options.
=== Serotonylation === Protein serotonylation refers to the post-translational modification in which serotonin is covalently attached to glutamine residues on substrate proteins via a transamidation reaction catalyzed by TGM2. Serotonylation is a type of monoaminylation, which itself refers to the overall class of post-translational modifications involving monoamines. However, monoaminylation reactions are further classified by the individual monoamine reactant they describe (ie., serotonylation, dopaminylation, histaminylation). Serotonylation has been reported for both histone and non-histone protein substrates, and thus represents a distinct neuroepigenetic and neuroproteomic regulatory mechanism with various implications in health and disease. Since 2003, multiple studies have revealed the critical role of serotonylation in mediating a wide range of physiological processes, both in the nervous system and beyond. Serotonylation is known to contribute to several significant diseases, including neuropsychiatric disorders such as depression and schizophrenia, as well as a variety of cancers. To date, notable protein serotonylation substrates include several metabolic enzymes (GAPDH, mTOR), Rab GTPases (Rab3a, Rab27a), Rho GTPases (RhoA, Rac1, Cdc42), proteins involved in muscle contractility (⍺-actinin, SERCA2a), extracellular matrix proteins (fibronectin), neural surface proteins, and Ras, as well as histone H3.
===== Laboratory specimen transport ===== PTS are widely used for routine and urgent specimen transport from wards and emergency departments to central laboratories. Studies show that, when validated, PTS can achieve fast transit times without degrading analytical quality; however, laboratories typically perform local validation because effects can vary by analyte and system design.
Noroxycodone is the major metabolite of the opioid analgesic oxycodone. It is formed from oxycodone in the liver via N-demethylation predominantly by CYP3A4. Noroxycodone binds to and activates the μ-opioid receptor (MOR) similarly to oxycodone, although with one-third of the affinity of oxycodone and 5- to 10-fold lower activational potency. However, although a potent MOR agonist, noroxycodone poorly crosses the blood-brain-barrier into the central nervous system, and for this reason, is only minimally analgesic in comparison.
=== Pharmacodynamics === Isoergine shows affinity for serotonin receptors labeled with serotonin or LSD in rat brain membranes. It has about 10- to 25-fold lower affinity for these receptors than serotonin or LSD and has the same affinity as ergine and iso-LSD (IC50Tooltip half-maximal inhibitory concentration = 100–200 nM for isoergine, 200 nM for ergine and iso-LSD, and 8–10 nM for LSD). No other receptor interaction data are available for isoergine as of 2020. However, computer-predicted receptor affinities are available for ergine/isoergine (stereochemistry not taken into account). The drug is said to have about 4.3% of LSD's antiserotonergic potency in vitro. It is 5- to 33-fold less potent than LSD in producing behavioral changes in the conditioned avoidance test in rodents.
Sources: en.wikipedia.org
It is a synthetic REV-ERB agonist used mainly in preclinical research. It is not an approved medicine for human use.
It binds to REV-ERBα and REV-ERBβ, nuclear receptors involved in circadian and metabolic gene regulation. This can alter transcription of genes related to lipid and glucose metabolism in experimental models.
No controlled human trials have established that effect. Endurance findings come primarily from rodent studies, and human responses remain unknown.
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.